InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
Telomir Pharmaceuticals (NASDAQ: TELO) announced the submission of an Investigational New Drug application to the FDA for Telomir-1 (Telomir-Zn) targeting advanced and metastatic triple-negative breast cancer, supported by preclinical efficacy and safety data demonstrating tumor growth reduction and favorable tolerability. Pending IND clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating the oral therapy, with a focus on safety, dose optimization and…